Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085584 (
encephalopathy
)
18,178
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vincristine sulfate
was inadvertently given intrathecally to a woman with lymphoma, producing ascending sensory and motor dysfunction followed by
encephalopathy
and death. Pathologically, neurons were swollen by aggregates of neurofilaments similar to the neurofilaments described in experimental models of vincristine neurotoxicity.
...
PMID:Fatal myeloencephalopathy caused by intrathecal vincristine. 689 62
A 66-year-old woman presented with new onset generalised tonic-clonic seizures following her first dose of chemotherapy comprising Rituximab, Cyclophosphamide, Hydroxydaunorubicin,
Oncovin
and Prednisolone (R-CHOP) 10 days earlier for non-Hodgkin's lymphoma. On admission, computed tomography (CT) scan of the cranium showed no abnormality. The CT was repeated within 48 hours as the patient developed status epilepticus and papilledema; the repeat scan showed characteristics of posterior reversible
encephalopathy
syndrome (PRES). Association of rituximab with this condition was suspected as there was no recurrence of PRES after receiving two more cycles of CHOP without rituximab. Contrary to previously published case reports, this patient had a delayed clinical presentation.
...
PMID:Rituximab as a possible cause of posterior reversible encephalopathy syndrome. 2339 43
In this review, the intention is to present the four clinical models of HIV-1-brain damage, named with the diffuse category of HIV-
encephalopathy
. It contains the past three decades, since the first static-infectological model of Snider WD, developed in 1983, based in a great neuropathological trial with AIDS patients. The second one, maybe the most compact of them, was the AIDS-dementia complex, published by the Navia BA group, in two notable papers published in 1986. This resulted in a consistent HIV-neuropsychiatric condition, till 1996, when HAART era begun. In a third early-HAART evolving model, we can find good correlations between the different levels: clinical (mild-moderate/severe forms), neuropsychological (subcortical pattern), neuroimaging, and
LCR
-markers. In the last-current paradigm, coincident with the advanced HAART treatments, the original HIV-
encephalopathy
became in a hybrid-complex compartimentalized condition, in contact with other neurodegenerative entities, like Alzheimer disease, Parkinson disease or the CNS-immune reconstitution inflammatory syndrome, with a high prevalence, atypical clinical forms, and with the demand of a specific management, in parallel to the systemic HIV disease.
...
PMID:[HIV- DEMENTIA. A REVIEW THIRTY FIVE YEARS AFTER (1981-2015)]. 2665 May 56